Zoekresultaten - You searched for Nucleic acid drugs

156 results

CMAST: New partnership launched to facilitate the development of new drugs for children across Europe

Read more

Convert Pharmaceuticals secures EUR 13,6 million to develop anti-cancer drugs

Read more

Rejuvenate Biomed awarded €460,000 grant from VLAIO to accelerate drug development for healthy aging

Read more

ViroVet and Pirbright join forces to develop African swine fever antivirals

Read more

Participation by Capricorn Venture Partners completes ViroVet’s series A funding

Read more

Trapping multidrug-resistant bacteria in molecular glue

Read more

Structure of the molecular machine that links carbohydrate and lipid metabolism

Read more

Scientists (dis)solve a century-long mystery to treat asthma and airway inflammation

Read more

Esperite (ESP), The Cell Factory demonstrate anti-inflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

Read more

Novel Nanobody to start clinical development in osteoarthritis - ablynx to receive €15 Million milestone payment

Read more

Ablynx receives fast track designation from the FDA for Caplacizumab for the treatment of acquired TTP

Read more

Ablynx announces 2017 half year results and year-to-date business update

Read more

CMAST supports Rejuvenate Biomed in their search for ways to impact the ageing process

Read more

ViroVet receives grant from VLAIO (Flanders) to boost the development of its disruptive vaccine technology

Read more

ViroVet wins pitching competition

Read more

Bone Therapeutics announces single intra-articular injection of viscosupplement JTA-004 delivered higher pain reduction than the reference in first study in knee osteoarthritis

Read more

Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis

Read more

Belgian PCR interpretation software company UgenTec partners with multiplex molecular diagnostics innovator PathoFinder

Read more

Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

Read more

EARLY PHASE DRUG DEVELOPMENT COURSE - FUTURE MEANS CREATIVITY

Read more

Bootcamp in Entrepreneurial Innovation in Orphan Diseases

Read more

REVERSED BREXIT: £250 MILLION FOR BART DE STROOPER'S DEMENTIA RESEARCH

Read more

Biogazelle offers unique mRNA sequencing on plasma

Read more

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

Read more

ThromboGenics NV : New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

Read more

VIB: A new unexpected key player in melanoma development identified

Read more

Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology

Read more

Helena Biosciences to develop automated blood test for chronic liver disease based on VIB and Ghent University research

Read more

ViroVet and GALVmed to collaborate on novel vaccines for sheep & goats

Read more

ThromboGenics NV to present THR-317 Pre-clinical Research Findings

Read more

Symposium on Liquid Biopsies & Cancer

Read more

Novel perspectives on anti-amyloid treatment for the prevention of Alzheimer’s disease

Read more

Scientists unravel role of glutamine synthetase in the spread of cancer

Read more

ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB

Read more

ThromboGenics Business Update - H1 2017

Read more

ONTOFORCE wins the EIT Venture Award 2017

Read more

ThromboGenics Business Update - Q3 2017

Read more

MyCartis appoints Philippe Stas as CEO

Read more

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Read more

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

Read more

VIB, CD3 and Galapagos NV enter into a license deal for the development of MALT1 inhibitors

Read more

Will 2018 be the year of biotech M&A? - An analysis by KBC Securities

Read more

BARC and Biogazelle announce collaboration for advanced genetic testing in clinical trials

Read more

ViroVet wins “start-up of the year” award

Read more

Closing in on Tau: Researchers identify a new synaptic player in early stages of neurodegeneration

Read more

So hot it hurts - Leuven researchers uncover ion channel trio that mediates painful heat sensing

Read more

Imec Presents Novel Organ-on-Chip Platform for Drug Screening

Read more

Mithra announces belux agreement with ceres pharma worth over eur 40 million

Read more

ThromboGenics Business Update - H1 2018

Read more

Gilead and Galapagos announce filgotinib meets primary and all key secondary endpoints in first phase 3 study in rheumatoid arthritis

Read more

Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis

Read more

Blockbuster Potential in Perimenopause with new E4 Candidate and Acceleration of Donesta Phase III Program

Read more

Oxurion NV Business Update - FY 2018

Read more

Biocartis Group NV: Biocartis Announces Global Collaboration with Covance

Read more

Bootcamp in Rare Diseases

Read more

Do ‘microglia’ hold the key to stop Alzheimer’s disease?

Read more

New social, ethical & economic impact studies and activities developed by Sanquin

Read more

5 Flemish universities reveal innovative state-of-the-art biotech research at knowledge for growth 2019

Read more

Terrific year for Belgian biotech companies

Read more

Preventing cell death as novel therapeutic strategy for rheumatoid arthritis

Read more

argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day

Read more

Sequana Medical announces presentation of positive DSR clinical proof-of-concept data demonstrating potential in volume overload due to heart failure

Read more

VIB: Towards a safer treatment for leukemia

Read more

flanders.bio provides you with insights in the vibrant life sciences sector

Read more

Ablynx announces warrant exercise

Read more

ABLYNX COMPLETES PATIENT RECRUITMENT IN ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF aTTP

Read more

ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE

Read more

Mithra to Initiate PK Study for Estelle®

Read more

Ablynx to present at upcoming USA Investor Conferences

Read more

Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Read more

Services

Read more

Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, at the annual European Congress of Rheumatology

Read more

Swissmedic has accepted for review the file on Cx601 for the treatment of Crohn's disease patients

Read more

Ablynx initiates a single and multiple dose phase I study of caplacizumab in healthy Japanese subjects

Read more

Ablynx achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, New Jersey, USA

Read more

Mithra Signs Exclusive License and Supply Agreement with Fuji Pharma for Donesta® in Japan and Asean

Read more

Publication in accordance with art. 14 of the Belgian Law regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx proposes appointment of Mrs. Hilde Windels as a new independent director

Read more

Ablynx & Sanofi enter into a strategic collaboration to develop nanobody product candidates

Read more

Ablynx will announce its 2017 half year results with webcast on 24 august 2017

Read more

Ablynx: publication in accordance with article 14 of the Belgian law regarding the publication of major shareholdings

Read more

Ablynx to present at upcoming investor conferences in London

Read more

Ablynx Announces Warrant Exercise

Read more

Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB® in Japan

Read more

Camel-IDS appoints Ruth Devenyns as Chief Executive Officer

Read more

Ablynx announces positive topline results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP

Read more

Ablynx files registration statement for a proposed global offering

Read more

Press Release - Life Sciences & Biotechnology

Read more

Ablynx - Publication in accordance with art.14 of the Belgian law of 2/05/2017 regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx - Publication in accordance with art.14 of the Belgian Law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx establishes subsidiary in the USA and appoints a general manager

Read more

Ablynx announces launch of proposed global offering

Read more

Ablynx prices $200 million Initial Public Offering in the United States

Read more

Suspension of trading in Ablynx shares on Euronext Brussels

Read more

Ablynx - Notice in Relation to the Convertible bonds due May 2020

Read more

Ablynx announces full exercise of underwriters' option to purchase additional shares and end of stabilization period

Read more

Ablynx closes $200 Million Initial Public Offering in the United States

Read more

Ablynx closes on underwriters' option to purchase $30 million of additional shares in the U.S. initial public offering

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

Ablynx - Correction of Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law) (1)

Read more

Ablynx to present at upcoming investor conferences in London and Paris

Read more

Ablynx: publication regarding the publication of major shareholdings

Read more

Ionis Pharmaceuticals licenses novel antisense drug for the treatment of centronuclear myopathy to dynacure

Read more

Ablynx: publication regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx announces results for the first nine months of 2017 and a year-to-date business update

Read more

MDxhealth teams up with Pharmaceutical Company Ferrer for distribution of its Prostate Cancer test SelectMDx in Spain

Read more

Ablynx - Results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP selected for presentation in the late-breaking abstracts session at the 2017 ASH annual meeting

Read more

Ablynx - Publication in accordance with §14 of the Belgian Law

Read more

Ablynx to host webcast about Phase III Hercules Study

Read more

Ablynx reports additional clinically important benefits of Caplacizumab from its Phase III Hercules Study in acquired TTP

Read more

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease

Read more

Ablynx announces positive data from its Japanese ethno-bridging study of Caplacizumab

Read more

Ablynx - notice in relation to waiver of lock-up restriction

Read more

Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies

Read more

Ablynx to present at the 36th annual J.P. Morgen Healthcare conference

Read more

iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor

Read more

Ablynx strongly believes unsolicited conditional proposal from Novo Nordisk fundamentally undervalues the company and its future prospects

Read more

Ablynx announces board changes

Read more

Press Release - Life Sciences & Biotechnology - 17/01/2018

Read more

Ablynx appoints dr. Robert Friesen as Chief Scientific Officer

Read more

Sanofi to acquire Ablynx for €3.9 Billion

Read more

Ablynx announces 2017 full year results

Read more

European Union provides Biocartis with up to EUR 24m debt financing facility for infectious disease projects

Read more

Ablynx commences dosing in its Phase II Study of ALX-0171 in hospitalised Japanese infants with a RSV infection

Read more

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe

Read more

Previously announced tender offers by Sanofi to acquire Ablynx will commence on april 4, 2018

Read more

Ablynx teams up with AIM for the design and implementation of its commercial supply chain for caplacizumab

Read more

Galapagos announces ISABELA Phase 3 program in IPF

Read more

Ablynx publication in accordance with article 14 of the belgian law of 2 may 2007

Read more

Ablynx completes patient recruitment in the Phase IIb Respire Study of its inhaled anti-RSV Nanobody ALX-0171

Read more

Ablynx announces Warrant Exercise

Read more

Sanofi and Ablynx announce the successful results of the initial tender offer period for ablynx and commencement of squeeze-out tender period

Read more

GST raises EUR 5 million to develop veterinary stem cell products

Read more

CoBioRes receives a € 1.7M grant from VLAIO to support its tetrapeptide prodrug research for treatment of Triple Negative Breast Cancer

Read more

GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Read more

Ablynx: Notice In Relation To The Convertible Bonds Due May 2020

Read more

Launch MBI LS&Health 2018 - 2019

Read more

Sanofi complets its acquisition of Ablynx following the expiration of the squeeze-out procedure

Read more

SCK•CEN seminar to discover the latest innovations in nuclear medicine

Read more

Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix

Read more

Press Release - Life Sciences & Biotechnology - 10/08/2018

Read more

NEW EARLY PHASE CLINICAL TRIALS PARADIGM - 6TH BIOPHARM DAY SEMINAR

Read more

Communicating Toxicology: What’s the Risk ?

Read more

Press Release - Life Sciences & Biotechnology - 18/09/2018

Read more

Galapagos: Positive trial results with filgotinib in psoriatic arthritis and ankylosing spondylitis both published in the lancet

Read more

Convert Pharmaceuticals appoints Mariola Söhngen as new CEO

Read more

reMYND raises 12 million EUR to assess clinical proof-ofmechanism in Alzheimer’s and to expand into orphan disorders

Read more

UNDER EMBARGO UNTIL 1 AM CET, DECEMBER 18th, 2018

Read more

Novosanis acquired by Orasure Technologies Inc

Read more

GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)

Read more

Novosanis enters into distribution deal with Fujirebio

Read more

flanders.health Personalised Medicine event

Read more

Registration open for the flanders.health partnering event on Personalised Medicine (28/05)

Read more

flanders.health Personalised Medicine event (28/11, Leuven)

Read more

Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients

Read more